Coronary heart disease with ejection fraction decreased heart failure
Conditions
Interventions
Experimental group:Guan-Xin Shu-Tong Capsule, Oral 3 capsules once, 3 times a day, for 12 weeks
Control group:Guanxin Shutong Capsule Simulator, Oral, 3 capsules once, 3 times a day, for 12 weeks
Sponsors
the Second Affiliated Hospital of Zhejiang University of Traditional Chinese Medicine
Eligibility
Sex/Gender
All
Age
18 Years to 80 Years
Inclusion criteria
Inclusion criteria: 1. meet the diagnosis of coronary disease and chronic ejection fraction decline heart failure; 2. meet the TCM syndrome diagnostic criteria of blood stasis syndrome; 3. Aged 40 to 80 years male and female; 4. screening NYHA heart function II and III period; 5. left ventricular ejection fraction (LVEF) <50% (by two-dimensional echocardiographic Simpson method); 6. the course of disease = 3 months, and the condition is stable within the recent 1 month, the standardized treatment is more than 1 month and the dose is stable; 7. plasma NT-proBNP=125ng/L; 8. volunteer, understand and sign informed consent.
Exclusion criteria
Exclusion criteria: 1. acute coronary syndrome (ACS) occurred in the past 1 month; 2. those who require cardiac surgery in the past 3 months or during the trial; 3. cardiogenic shock, acute myocarditis, uncontrollable malignant arrhythmia, hypertrophic obstructive cardiomyopathy, severe valvular disease requiring surgery and pulmonary embolism; 4. uncontrolled hypertension (systolic blood pressure =180mmHg, diastolic blood pressure >110mmHg) or hypotension (resting blood pressure) <90/50mmHg; 5. patients with severe liver and kidney dysfunction and patients with active liver disease, and / or AST, ALT = 3 times the upper limit of normal; 6. psychiatric patients, or patients with severe depression, a history of alcohol or drug abuse; 7. pregnant women, lactating women and those who are preparing to give birth during the period of taking the medicine or within 3 months after stopping the medicine; 8. allergic or those who have been allergic to multiple drugs or who are allergic to the ingredients in the study; 9. patients with a history of cancer or existing cancer, or pathological examination confirmed precancerous lesions; 10. those who participated in other clinical studies 3 months before the trial, and other patients who considered it inappropriate to participate in the study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| 6min walking distance test (6MWT) improvement value; | — |
Secondary
| Measure | Time frame |
|---|---|
| NT-proBNP content change;NYHA heart function classification;Minnesota Heart Failure Quality of Life Scale (MLHFQ);Echocardiography;TCM syndrome improvement;Compound endpoint event rate; | — |
Countries
China
Contacts
Public ContactHaitong Wan
Zhejiang University of Traditional Chinese Medicine
Outcome results
None listed